Fig. 4From: Early onset of efficacy with erenumab in patients with episodic and chronic migrainePercentage of patients with episodic migraine (a) chronic migraine (b) with a migraine day and 7-day moving averages for the 4-week baseline period and first 4-weeks of double-blind treatment (top panel) and for the last week of baseline and first 2 weeks of double-blind treatment (bottom panel)Back to article page